Physician profile
Jun T Park
NPI 1437333515
$17,148.86
in general payments reported to CMS, 2019-2025
15 companies · $4,565 in 2025
The $4,565 reported for 2025 was more than what 85% of Neurology With Special Qualifications In Child Neurology providers received nationally (typical 2025 total: $275).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $812 · 2020: $136 · 2021: $55.88 · 2022: $182 · 2023: $4,503 · 2024: $6,895 · 2025: $4,565.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,426 · Consulting Fee: $4,398 · Honoraria: $4,000 · Food and Beverage: $933 · Travel and Lodging: $189 · Education: $16.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,426.00 |
| Consulting Fee | $4,398.22 |
| Honoraria | $4,000.00 |
| Food and Beverage | $933.14 |
| Travel and Lodging | $189.15 |
| Education | $16.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $6,869.00 | 2023-2025 | Valtoco |
| Aucta Pharmaceuticals, INC. | $4,398.22 | 2025 | Motpoly Xr |
| Catalyst Pharmaceuticals, INC. | $4,354.32 | 2023-2024 | Fycompa |
| Eisai INC. | $406.62 | 2019-2022 | |
| Ucb, INC. | $384.59 | 2019-2025 | Briviact, Nayzilam |
| Sk Life Science, INC. | $165.30 | 2023-2025 | |
| Greenwich Biosciences, INC. | $123.05 | 2019 | |
| Mallinckrodt Enterprises LLC | $120.23 | 2019 | |
| Sunovion Pharmaceuticals INC. | $103.62 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $61.47 | 2023-2024 | |
| Novo Nordisk INC | $44.04 | 2025 | Ozempic, Rybelsus, Wegovy |
| Supernus Pharmaceuticals, INC. | $42.00 | 2019 | |
| Opko Pharmaceuticals, LLC | $33.89 | 2019 | |
| Aquestive Therapeutics, INC. | $23.32 | 2019 | |
| Novartis Pharmaceuticals Corporation | $19.19 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jun Park listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.